EC1169 PSMA-tubulysin (Prostate cancer)

Delivers A Potent Cytotoxic Agent To Cancer Cells That Express Prostate-Specific Membrane Antigen (PSMA)

EC1169 is an investigational, proprietary, injectable, PSMA-targeted SMDC consisting of a potent cytotoxic agent, tubulysin B hydrazide (TubBH). TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. EC1169 is being co-developed with EC0652 as its companion imaging agent.

Development Stage

EC1169 is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer.

  • * The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.